加载中...

MedXY News - metformin

MedXY AI/MedXY News/Tag: metformin

MedXY News

EnglishTag

metformin

44 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational

Section: CardiologyNov 14, 2025

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial

Metformin Does Not Improve Walking Distance in Peripheral Artery Disease: Results from the PERMET Randomized Trial

The PERMET randomized, double-blind trial found that 6 months of metformin did not improve 6-minute walk distance or other functional endpoints in people with lower extremity peripheral artery disease (PAD) without diabetes.

Section: CardiologyNov 9, 2025

Metformin in Knee Osteoarthritis: Evaluating Its Role in Pain Relief and Disease Modification

Metformin in Knee Osteoarthritis: Evaluating Its Role in Pain Relief and Disease Modification

Emerging evidence supports metformin’s modest pain-relieving effects and potential disease-modifying properties in knee osteoarthritis patients with overweight or obesity, warranting further investigation through larger trials.

Section: Clinical UpdatesNov 2, 2025

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

SGLT2 Inhibitors Linked to Lower Parkinson’s Disease Risk Than Metformin in Type 2 Diabetes: Large Real‑World TriNetX Study Signals Class Neuroprotection

A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective

Section: Diabetes & EndocrinologyNov 1, 2025

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial

Over 21 years, intensive lifestyle changes and metformin significantly reduced type 2 diabetes incidence in at-risk adults, with variable effects based on individual baseline risk factors, highlighting opportunities for precision prevention

Section: Diabetes & EndocrinologyOct 29, 2025

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression

Metformin and Age-Related Macular Degeneration: Current Evidence on Development and Progression

This review synthesizes current evidence from large cohorts, meta-analyses, and randomized trials evaluating metformin’s association with AMD development and progression, highlighting a nuanced but inconclusive protective potential requirin

Section: OphthalmologyOct 22, 2025

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial

This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately con

Section: Clinical UpdatesOct 8, 2025

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology stra

Section: Clinical UpdatesOct 8, 2025

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

Enhanced Therapeutic Benefits of Combined Metformin and Curcumin in Women with Polycystic Ovary Syndrome: Results from a Factorial Clinical Trial

A 12-week randomized trial demonstrates that combining metformin and nanocurcumin significantly improves lipid metabolism, glucose regulation, hormonal balance, and body metrics in women with PCOS, surpassing effects seen with either agent

Section: Diabetes & EndocrinologyOct 8, 2025

Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial

Metformin with or without Mediterranean Diet Significantly Reduces Diabetes Risk in Metabolic Syndrome: Insights from the MeMeMe Trial

The MeMeMe randomized trial shows that metformin 1,700 mg/day effectively prevents type 2 diabetes in metabolic syndrome patients, independent of Mediterranean diet adherence, with implications for age-related disease prevention.

Section: Diabetes & EndocrinologyOct 8, 2025

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-d

Section: Clinical UpdatesOct 8, 2025

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

This review synthesizes recent evidence on metformin’s therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-free and

Section: Clinical UpdatesOct 8, 2025

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

Metformin as an Adjunct to Chemoradiotherapy in Locally Advanced Cervical Cancer: Insights on Safety, Tolerability, and Feasibility from a Phase II Randomized Trial

This phase II study shows that adding metformin to standard chemoradiotherapy in locally advanced cervical cancer is safe, well tolerated, and feasible, with no significant increase in severe adverse events and successful biomarker-based tu

Section: Clinical UpdatesOct 8, 2025

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm,

Section: OB/GYN & Women's HealthOct 8, 2025

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Section: Clinical UpdatesOct 8, 2025

$Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy$

Phase Ib Trial of Metformin Combined with Nivolumab in Refractory Solid Tumors: Safety, Dosage, and Preliminary Efficacy

A phase Ib study evaluated the safety, optimal dosing, pharmacokinetics, and preliminary efficacy of metformin with nivolumab in refractory solid tumors, showing good tolerability and promising responses in a subset of patients.

Section: newsOct 8, 2025

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in

Section: Clinical UpdatesOct 8, 2025

Metformin: The Surprising Anti-Aging Ally Rewinding the Biological Clock

Metformin: The Surprising Anti-Aging Ally Rewinding the Biological Clock

Recent research reveals metformin’s potential to reverse biological aging by up to 20 years, igniting hope for anti-aging therapies and raising questions about its wider use.

Section: Family Medicine & NutritionOct 8, 2025

Metformin and COVID-19 Symptom Resolution: Evidence from the ACTIV-6 Randomized Clinical Trial

Metformin and COVID-19 Symptom Resolution: Evidence from the ACTIV-6 Randomized Clinical Trial

This review synthesizes recent evidence from the ACTIV-6 trial showing metformin does not significantly reduce symptom duration in low-risk adults with COVID-19, addressing safety, clinical outcomes, and translational insights.

Section: Clinical UpdatesOct 8, 2025

Unmasking Fructose: How a Common Sweetener Sparks Immune Attacks and Inflammatory Bowel Disease—And How Metformin Offers Hope

Unmasking Fructose: How a Common Sweetener Sparks Immune Attacks and Inflammatory Bowel Disease—And How Metformin Offers Hope

High fructose intake can directly activate immune cells, worsening intestinal inflammation linked to IBD, but the diabetes drug metformin shows promise in reversing these effects.

Section: Family Medicine & NutritionOct 6, 2025

Prev 1 2 3 Next